Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Centessa Pharmaceuticals plc

Market Cap 6.22B 5.46B 5.03B 4.71B 8.83B 589B 8.99B 60.48B 23.37B 289B 23.34B 22.83B 1,004B P/E 2026 *
-26x
P/E 2027 * -23.1x
Enterprise Value 6.22B 5.46B 5.03B 4.71B 8.83B 589B 8.99B 60.48B 23.37B 289B 23.34B 22.83B 1,004B EV / Sales 2026 *
-
EV / Sales 2027 * 311x
Free-Float
78.43%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week+1.86%
Current month+1.86%
1 month+1.89%
3 months+49.67%
6 months+59.57%
Current year+61.94%
1 week 39.69
Extreme 39.69
40.56
1 month 39.58
Extreme 39.58
40.56
Current year 21.5
Extreme 21.5
40.56
1 year 12.74
Extreme 12.74
40.56
3 years 5.15
Extreme 5.15
40.56
5 years 2.88
Extreme 2.885
40.56
10 years 2.88
Extreme 2.885
40.56
Manager TitleAgeSince
Chief Executive Officer 40 01/01/2026
Director of Finance/CFO 53 10/06/2024
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 63 23/02/2021
Chairman 56 01/11/2020
Director/Board Member 53 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
05-01Tax

Chief Executive Officer

-604 0.0004%
03-26Fiscal year

Head of Human Resources

123,228 0.0922%
03-26Fiscal year

Executive/Senior Manager

71,994 0.0539%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%+1.86%+225.82%+537.80% 6.22B
+2.96%+4.08%-8.03%-2.24% 43.24B
+2.23%+5.90%+327.41%+578.85% 35.25B
+1.59%+2.96%+11.76%+48.53% 30.22B
+2.07%-3.99%+10.70%-19.82% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+4.64%+6.85% - - 14.16B
+3.91%+1.28%+53.05%+110.81% 13.01B
+2.77%+2.93%+9.65%+11.90% 12.7B
+0.13%+2.74%+103.13%+84.44% 12.54B
Average +1.63%-0.60%+81.93%+151.57% 21.94B
Weighted average by Cap. +1.63%-0.67%+75.28%+134.22%

Financials

2026 *2027 *
Net sales - 20M 17.57M 16.19M 15.15M 28.41M 1.89B 28.92M 195M 75.18M 929M 75.08M 73.46M 3.23B
Net income -243M -214M -197M -184M -345M -23.04B -352M -2.37B -914M -11.3B -913M -893M -39.29B -262M -230M -212M -198M -372M -24.81B -379M -2.55B -985M -12.17B -983M -962M -42.31B
Net Debt - -
Logo Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Employees
129
Date Price Change Volume
23/06/26 $40.50 +0.80% 11,266,599
22/06/26 $40.18 +0.40% 3,758,569
18/06/26 $40.02 +0.38% 5,588,743
17/06/26 $39.87 +0.30% 2,943,859
16/06/26 $39.75 -0.03% 2,216,243
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
40.18USD
Average target price
44.17USD
Spread / Average Target
+9.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNTA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!